BioNTech Signs a Purchase Agreement to Acquire Kite’s Cell Therapy, R&D Platform and Manufacturing Facility in Gaithersburg, MD

 BioNTech Signs a Purchase Agreement to Acquire Kite’s Cell Therapy, R&D Platform and Manufacturing Facility in Gaithersburg, MD

Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19

Shots:

  • Kite will receive a one-time upfront to purchase Kite’s individualized solid tumor neoantigen TCR discovery platform, R&D & clinical manufacturing facility in Gaithersburg. The Transaction is expected to be close at the end of Jul’21
  • BioNTech will use the Kite’s facility to support clinical trials in the US & will add its cell therapy manufacturing facility in Idar-Oberstein, Germany
  • The agreement will strengthen BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adds the manufacturing footprint in North America

Click here to read full press release/ article | Ref:  Globenewswire | Image: Money Control

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post